Hydroxocobalamin in the treatment of vasodilatory shock

A 58-year-old, 85 kg man with coronary artery disease status post coronary artery bypass grafting, and insulin dependent diabetes mellitus complicated by diabetic nephropathy and end stage renal disease underwent a cadaveric renal transplantation. A Swan-Ganz catheter was placed which revealed norma...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical anesthesia 2020-05, Vol.61, p.109665-109665, Article 109665
Main Authors: Carullo, Philip C., Al-Khafaji, Ali
Format: Article
Language:English
Subjects:
Cardiovascular disease
Coronary vessels
Hemodialysis
Humans
Hydroxocobalamin
Hypotension
Shock - drug therapy
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 58-year-old, 85 kg man with coronary artery disease status post coronary artery bypass grafting, and insulin dependent diabetes mellitus complicated by diabetic nephropathy and end stage renal disease underwent a cadaveric renal transplantation. A Swan-Ganz catheter was placed which revealed normal cardiac output (7.3 l/min), low central venous pressure (1 mmHg) and low systemic vascular resistance (634 dynes/cm2). Here we report the successful use of hydroxocobalamin for treatment of vasodilatory shock in a post renal transplant patient in the ICU.Financial disclosures None.Declaration of competing interest This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
ISSN:0952-8180
1873-4529
DOI:10.1016/j.jclinane.2019.109665